{"product_id":"nanovaccinology-as-targeted-therapeutics-hardback-9781119857341","title":"Nanovaccinology as Targeted Therapeutics (Hardback) 9781119857341","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eNanovaccinology as Targeted Therapeutics\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eKaushik Pal (Edited by), K Pal (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781119857341, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 31 August 2022\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e352 pages\u003cbr\u003e1 x 1 x 1 cm, 0.454 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cb\u003eNANOVACCINOLOGY AS TARGETED THERAPEUTICS\u003c\/b\u003e  \u003cp\u003e\u003cb\u003eThe book presents the early-stage development of nanovaccines that could well be the new generation of vaccines which have a great potential for the prevention and treatment of many diseases.\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eNanovaccinology as Targeted Therapeutics \u003c\/i\u003eexplores recent breakthroughs in the exciting new field of micro- and nanofabricated engineered nanomaterials. In addition to spectroscopic characterizations, significant topics for interdisciplinary research, especially in the fields of nanogels, which deal with polymer chemistry, nanotechnology, materials science, pharmaceuticals, and medicine are explored, where their small dimensions prove highly advantageous. Nanovaccinology could potentially revolutionize conventional therapy and diagnostic methods due to its superior effectiveness over its macro-sized counterparts in almost all biomedical areas. Strong interest in this novel class of material has driven many studies to discover biogenic production methods and new areas of potential utilization in this area. Therefore, it is important to keep abreast of the development of these biomedical research aspects highlighted in the 19 chapters of this book written in diverse fields of studies, and their emerging applications utilized in next-generation techniques.  \u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAudience\u003c\/b\u003e\u003cbr\u003e Biotechnologists, nanotechnologists, materials scientists, biochemists, medical biologists, drug delivery and formulation chemists, virologists and pharmacists.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Nanotechnology in Vaccine Development and Constraints 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eTahmina Foyez and Abu Bin Imran\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 2\u003c\/p\u003e \u003cp\u003e1.2 Nanoparticles, an Alternative Approach to Conventional Vaccines 4\u003c\/p\u003e \u003cp\u003e1.3 Nanoparticles as Vaccine Delivery Vehicle 5\u003c\/p\u003e \u003cp\u003e1.4 Nanotechnology to Tackle the Challenges of Vaccine Delivery 6\u003c\/p\u003e \u003cp\u003e1.4.1 Polymeric Nanoparticles 6\u003c\/p\u003e \u003cp\u003e1.4.2 Inorganic Nanoparticles 7\u003c\/p\u003e \u003cp\u003e1.4.3 Biomolecular Nanoparticles 8\u003c\/p\u003e \u003cp\u003e1.4.4 Liposome 9\u003c\/p\u003e \u003cp\u003e1.4.5 Virus-Like Particles 9\u003c\/p\u003e \u003cp\u003e1.4.6 Micelles 9\u003c\/p\u003e \u003cp\u003e1.4.7 Immunostimulating Complexes 10\u003c\/p\u003e \u003cp\u003e1.4.8 Self-Assembled Proteins (SAPNs) 10\u003c\/p\u003e \u003cp\u003e1.4.9 Emulsions 11\u003c\/p\u003e \u003cp\u003e1.5 Constraints and Challenges of Nanovaccines 11\u003c\/p\u003e \u003cp\u003e1.6 Concluding Remarks 12\u003c\/p\u003e \u003cp\u003eAcknowledgments 13\u003c\/p\u003e \u003cp\u003eReferences 13\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Nanomedicine and Nanovaccinology Tools in Targeted Drug Delivery 21\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eBogala Mallikharjuna Reddy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 21\u003c\/p\u003e \u003cp\u003e2.2 Nanomaterial-Based Drug Delivery Tools 25\u003c\/p\u003e \u003cp\u003e2.2.1 Inorganic Nanoparticles 26\u003c\/p\u003e \u003cp\u003e2.2.2 Polymeric Nanoparticles 26\u003c\/p\u003e \u003cp\u003e2.2.3 Dendrimers 27\u003c\/p\u003e \u003cp\u003e2.2.4 Liposomes 28\u003c\/p\u003e \u003cp\u003e2.2.5 Micelles 29\u003c\/p\u003e \u003cp\u003e2.2.6 Emulsions 30\u003c\/p\u003e \u003cp\u003e2.2.7 Carbon-Based Nanomaterials 30\u003c\/p\u003e \u003cp\u003e2.2.8 Self-Assembled Proteins 31\u003c\/p\u003e \u003cp\u003e2.2.9 Immunostimulating Complexes 32\u003c\/p\u003e \u003cp\u003e2.2.10 Virus-Like Particles 33\u003c\/p\u003e \u003cp\u003e2.3 Targeted Drug Delivery Applications 33\u003c\/p\u003e \u003cp\u003e2.3.1 Cancer 36\u003c\/p\u003e \u003cp\u003e2.3.2 Neurology 37\u003c\/p\u003e \u003cp\u003e2.3.3 Cardiology 38\u003c\/p\u003e \u003cp\u003e2.3.4 Ophthalmology 38\u003c\/p\u003e \u003cp\u003e2.3.5 Pulmonology 39\u003c\/p\u003e \u003cp\u003e2.3.6 Tissue Engineering 40\u003c\/p\u003e \u003cp\u003e2.3.7 Viral Infections 40\u003c\/p\u003e \u003cp\u003e2.3.8 Other Miscellaneous Types 41\u003c\/p\u003e \u003cp\u003e2.4 Commercial Nanodelivery Tools 42\u003c\/p\u003e \u003cp\u003e2.4.1 Industrial Manufacturing 42\u003c\/p\u003e \u003cp\u003e2.4.2 Advantages and Disadvantages 44\u003c\/p\u003e \u003cp\u003e2.4.3 Risks and Challenges 45\u003c\/p\u003e \u003cp\u003e2.5 Conclusions and Future Prospects 46\u003c\/p\u003e \u003cp\u003eAcknowledgments 47\u003c\/p\u003e \u003cp\u003eReferences 47\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Nanovaccinology and Superbugs 53\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSandhya Kalathilparambil Santhosh, Kaviya Parampath Kootery, Mridul Umesh, Preethi Mariam Alex, Meghna Mani, Adina Roy and Suma Sarojini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 54\u003c\/p\u003e \u003cp\u003e3.2 Need for Nanovaccines 55\u003c\/p\u003e \u003cp\u003e3.3 Types of Nanovaccines 57\u003c\/p\u003e \u003cp\u003e3.3.1 Subunit Vaccines 57\u003c\/p\u003e \u003cp\u003e3.3.2 Conjugate Vaccines 58\u003c\/p\u003e \u003cp\u003e3.3.3 RNA Vaccines 58\u003c\/p\u003e \u003cp\u003e3.3.4 Reverse Vaccinology 59\u003c\/p\u003e \u003cp\u003e3.3.5 Biomimetic Nanovaccines 60\u003c\/p\u003e \u003cp\u003e3.3.5.1 Biomimetic Membranes 60\u003c\/p\u003e \u003cp\u003e3.3.5.2 Outer Membrane Vesicle Nanoparticles 61\u003c\/p\u003e \u003cp\u003e3.3.6 Nanotoxoids 62\u003c\/p\u003e \u003cp\u003e3.3.7 Liposomes 63\u003c\/p\u003e \u003cp\u003e3.3.8 Polymeric Nanoparticles 63\u003c\/p\u003e \u003cp\u003e3.3.9 Virus-Like Particle 64\u003c\/p\u003e \u003cp\u003e3.3.10 Inorganic Nanoparticles 65\u003c\/p\u003e \u003cp\u003e3.4 Mechanism of Action of Nanovaccines 65\u003c\/p\u003e \u003cp\u003e3.5 Limitations of Nanovaccines 68\u003c\/p\u003e \u003cp\u003e3.6 Conclusion 69\u003c\/p\u003e \u003cp\u003eAcknowledgment 69\u003c\/p\u003e \u003cp\u003eReferences 69\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Current Research Trends on SARS-CoV2 Virus Against Nanovaccine Formulation 77\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePushpalatha C., Chhaya Kumar, Sowmya S.V., Dominic Augustine, Elizabeth Abbu Varghese and Jithya Suresh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 78\u003c\/p\u003e \u003cp\u003e4.2 COVID-19\/SARS-CoV2 Pathophysiology 78\u003c\/p\u003e \u003cp\u003e4.3 Development of Nanovaccines Against SARS-CoV 2 79\u003c\/p\u003e \u003cp\u003e4.4 Biomimetic Nanovaccines Against SARS-CoV 2 80\u003c\/p\u003e \u003cp\u003e4.4.1 Virus-Like Particles 84\u003c\/p\u003e \u003cp\u003e4.4.2 Nucleic Acids Vaccines 85\u003c\/p\u003e \u003cp\u003e4.4.3 Protein Vaccines 86\u003c\/p\u003e \u003cp\u003e4.5 Translatable Subunit Nanovaccine Against SARS-CoV 2 86\u003c\/p\u003e \u003cp\u003e4.6 Separable Microneedle Patch Nanovaccine 86\u003c\/p\u003e \u003cp\u003e4.7 Polymer-Based Nanovaccines 87\u003c\/p\u003e \u003cp\u003e4.8 Pharmaceutical Challenges of SARS-CoV2 Nanovaccines 88\u003c\/p\u003e \u003cp\u003e4.9 Future Prospects of SARS-CoV2 Nanovaccines 89\u003c\/p\u003e \u003cp\u003e4.10 Challenges and Limitations 89\u003c\/p\u003e \u003cp\u003e4.11 Conclusion and Outlook 91\u003c\/p\u003e \u003cp\u003eReferences 91\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Nanovaccinology Against Infectious Disease 95\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eS. Chakroborty and P. Panda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 96\u003c\/p\u003e \u003cp\u003e5.2 Nanovaccinology Against Bacterial Disease 97\u003c\/p\u003e \u003cp\u003e5.3 Nanovaccinology Against Viral Disease 99\u003c\/p\u003e \u003cp\u003e5.4 Nanovaccinology Against Cancer 101\u003c\/p\u003e \u003cp\u003e5.5 Nanovaccinology Against Parasite-Born Disease 108\u003c\/p\u003e \u003cp\u003e5.6 Nanovaccinology Against Autoimmune Disorders 109\u003c\/p\u003e \u003cp\u003e5.7 Conclusion and Outlook 110\u003c\/p\u003e \u003cp\u003eAcknowledgments 110\u003c\/p\u003e \u003cp\u003eReferences 110\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Preclinical and Commercial Trials of Cancer Diagnosis via Nano-Imaging and Nanovaccinology 115\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSowmya S.V., Pushpalatha C., Dominic Augustine, Sibikar P., Bharkhavy K.V. and Elizabeth Abbu Varghese\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 116\u003c\/p\u003e \u003cp\u003e6.2 Role of Nano-Imaging in Cancer Diagnosis, Progression, and Treatment 117\u003c\/p\u003e \u003cp\u003e6.2.1 Gold Nanoparticles 117\u003c\/p\u003e \u003cp\u003e6.2.2 Quantum Dots 118\u003c\/p\u003e \u003cp\u003e6.2.3 Carbon Nanotubes 118\u003c\/p\u003e \u003cp\u003e6.2.4 Nanowires 118\u003c\/p\u003e \u003cp\u003e6.2.5 Cantilevers and Nanopores 118\u003c\/p\u003e \u003cp\u003e6.2.6 Other Types of Nanoparticles 118\u003c\/p\u003e \u003cp\u003e6.3 Challenges in the Translation of Nanotechnology-Based Imaging Methods Into Clinical Application 119\u003c\/p\u003e \u003cp\u003e6.4 Nanovaccines for Cancer Immunotherapy 119\u003c\/p\u003e \u003cp\u003e6.4.1 Composition of Nanovaccines in Cancer Therapy 120\u003c\/p\u003e \u003cp\u003e6.4.1.1 Antigens 120\u003c\/p\u003e \u003cp\u003e6.4.1.2 Immunostimulatory Adjuvants 121\u003c\/p\u003e \u003cp\u003e6.4.1.3 Nanocarriers 121\u003c\/p\u003e \u003cp\u003e6.5 Functionalities of Nanocarriers for the Delivery of Cancer Vaccines 122\u003c\/p\u003e \u003cp\u003e6.5.1 Efficient Delivery of Vaccines by Nanocarriers 123\u003c\/p\u003e \u003cp\u003e6.5.2 Co-Delivery of Antigens and Adjuvants via Nanocarriers 123\u003c\/p\u003e \u003cp\u003e6.5.3 Nanocarriers Potentiate Immunomodulation Through Multivalent Antigens and\/or Adjuvants 123\u003c\/p\u003e \u003cp\u003e6.5.4 Self-Adjuvanted Nanocarriers 123\u003c\/p\u003e \u003cp\u003e6.6 Nanovaccine Strategies in Cancer 123\u003c\/p\u003e \u003cp\u003e6.6.1 STING Agonist-Based Nanovaccines 124\u003c\/p\u003e \u003cp\u003e6.6.2 Neoantigen Nanovaccines 124\u003c\/p\u003e \u003cp\u003e6.6.3 mRNA-Based Nanovaccines 124\u003c\/p\u003e \u003cp\u003e6.6.4 aAPCs 124\u003c\/p\u003e \u003cp\u003e6.6.5 Nanovaccines for Combination Therapy 124\u003c\/p\u003e \u003cp\u003e6.7 Preclinical and Clinical Trials of Applications of Nanoimaging and Nanovaccinology in Cancer 125\u003c\/p\u003e \u003cp\u003e6.8 Recent Developments in the Trials of Nanovaccinology in Cancer 126\u003c\/p\u003e \u003cp\u003e6.9 Perspectives and Future Directions 127\u003c\/p\u003e \u003cp\u003e6.10 Conclusions 127\u003c\/p\u003e \u003cp\u003eReferences 127\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Biomedical and Electronic Tune-Ups of 2C4NA Nanocrystalline Sample 131\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaalmarugan J., Egbert Selwin Rose A., Anbarasan P., Poorani R., Aarthi N., Ganesan H., Senthil Kannan K. and Flora G.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 132\u003c\/p\u003e \u003cp\u003e7.2 Computational, Tribological, Fluorescence, and Influx Study 133\u003c\/p\u003e \u003cp\u003e7.3 Antidiabetic (AD) Study, Anticancer Study, and Anti-Inflammatory Study 138\u003c\/p\u003e \u003cp\u003e7.4 Conclusion 139\u003c\/p\u003e \u003cp\u003eReferences 139\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Biological, Electronic-Filter, Influx and Theoretical Practicalities of 2-Chloro-6-Nitroaniline (2C6NA) Crystals for Biomedical and Microelectronics Tasks 145\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaria Sumathi B., Maalmarugan J., Ganesan H., Saravanan P., Patel R.P., Sheeba M., Flora G. and Senthil Kannan K.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 146\u003c\/p\u003e \u003cp\u003e8.2 Computational and Influx 146\u003c\/p\u003e \u003cp\u003e8.3 Antibacterial, Antifungal, Antidiabetic, DPPH, FRAP, Anticancer 148\u003c\/p\u003e \u003cp\u003e8.4 Conclusion 150\u003c\/p\u003e \u003cp\u003eReferences 151\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Antidiabetic, Anti-Oxidant, Computational, Filter, and Tribological Characterizations of Bis Glycine Lithium Bromide Monohydrate Nano (32 nm) Scaled Crystals 157\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDayana Lobo F., Senthil Kannan K., Mathivanan V., Jacintha Tamil Malar A., Christy S., Flora G., Ganesan H. and Maalmarugan J.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 158\u003c\/p\u003e \u003cp\u003e9.2 Experimental 158\u003c\/p\u003e \u003cp\u003e9.2.1 Synthesis 158\u003c\/p\u003e \u003cp\u003e9.3 Results and Discussions 159\u003c\/p\u003e \u003cp\u003e9.3.1 Single Crystalline XRD (SXRD) Study and Powder XRD (PXRD) Studies 159\u003c\/p\u003e \u003cp\u003e9.3.2 Fluorescence (FL) Study for 32-nm Scale 160\u003c\/p\u003e \u003cp\u003e9.3.3 Antidiabetic (AD) Study and Influx Study 160\u003c\/p\u003e \u003cp\u003e9.3.4 AO-DPPH, FRAP of Antioxidant Activity 162\u003c\/p\u003e \u003cp\u003e9.3.5 Tribology—Load Capacity by the Compressive Strength Model of the Polymeric Bearings, Software-Based Thermal Ellipsoidal Plot 162\u003c\/p\u003e \u003cp\u003e9.4 Conclusion 164\u003c\/p\u003e \u003cp\u003eReferences 164\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Device Utility, Energy, and Bioutility of N2MNM4MBH Macro, Nano Models 169\u003cbr\u003e \u003c\/b\u003e\u003ci\u003ePauline Jenifer S., Flora G., Zozimus Divya Lobo C., Charles A., Senthil Kannan K., Anbuvel D., Prajith V. and Jemma Hermelin Jesy Diaz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 170\u003c\/p\u003e \u003cp\u003e10.2 Synthesis and XRD 171\u003c\/p\u003e \u003cp\u003e10.3 Influx 171\u003c\/p\u003e \u003cp\u003e10.4 Computational 171\u003c\/p\u003e \u003cp\u003e10.4.1 Antidiabetic Study 171\u003c\/p\u003e \u003cp\u003e10.5 Conclusion 177\u003c\/p\u003e \u003cp\u003eReferences 177\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Biocurative, Tribological, Electro-Functionalities of ZnO-MIZN Nanoparticles 183\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSenthil Kannan K., Prabhjeet Kaur Dhillon, Jemma Hermelin Jesy Diaz, Padmavathi P., Flora G., Irudhya Sahaya Lancy S., Jeeva Rani Thangam G. and Sheeba M.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 184\u003c\/p\u003e \u003cp\u003e11.2 Antibacterial Activity 185\u003c\/p\u003e \u003cp\u003e11.3 XRD and Magnetic Effect 186\u003c\/p\u003e \u003cp\u003e11.4 Tribological Data for Nano Sample Coatings of ZnO-MIZN 189\u003c\/p\u003e \u003cp\u003e11.5 Filter Utility 189\u003c\/p\u003e \u003cp\u003e11.6 Conclusion 190\u003c\/p\u003e \u003cp\u003eReferences 190\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Nanotubular Device Effect, Super Cell Effectiveness, Hirshfeld Energy Analysis and Biomedicinal Efficacy of 2-Fluoro-5-Nitro-Aniline (2F5NA) Crystals 195\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eFlora G., Munikumari A., Sheeba M., Jemma Hermelin Jesy Diaz, Senthil Kannan K., Ponrathy T., Muthu Sheeba M. and Joshua Steve Abishek B.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 196\u003c\/p\u003e \u003cp\u003e12.2 XRD and Computational 197\u003c\/p\u003e \u003cp\u003e12.3 Bioutility 207\u003c\/p\u003e \u003cp\u003e12.3.1 Antibacterial of 2F5NA Crystals 207\u003c\/p\u003e \u003cp\u003e12.4 Conclusion 208\u003c\/p\u003e \u003cp\u003eReferences 208\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Nano, Peptide Link, Pharma Impact and Electron Density of AMPHB Macro, Nano Crystalline Samples 213\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSenthil Kannan K., Dayana Lobo F., Gayathri A., Prathebha K., Jacintha Tamil Malar A., Maria Sumathi B., Flora G. and Egbert Selwin Rose A.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 214\u003c\/p\u003e \u003cp\u003e13.2 Characterizations 215\u003c\/p\u003e \u003cp\u003e13.2.1 XRD and Computational Impactness 215\u003c\/p\u003e \u003cp\u003e13.2.2 Antidiabetic (AD), Anti-Inflammatory (AI), and Anti-Fungal (AF) Effect of AMPHB Macro and Nano Crystals 219\u003c\/p\u003e \u003cp\u003e13.3 Conclusion 220\u003c\/p\u003e \u003cp\u003eReferences 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Super Lattice, Computational Interactions and Bio-Uses of CPDMDP Crystals 227\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eFlora G., Christy S., Shobana V., Divya R., Jemma Hermelin Jesy Diaz, Pauline Jenifer S., Senthil Kannan K. and Jacintha Tamil Malar A.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 228\u003c\/p\u003e \u003cp\u003e14.2 Computational 229\u003c\/p\u003e \u003cp\u003e14.3 Synthesis 234\u003c\/p\u003e \u003cp\u003e14.4 Xrd 234\u003c\/p\u003e \u003cp\u003e14.5 Influx of CPDMDP of Both Scales 235\u003c\/p\u003e \u003cp\u003e14.6 Antidiabetic Activity of Macro, Nano CPDMDP Crystals 235\u003c\/p\u003e \u003cp\u003e14.7 Antioxidant Activity 236\u003c\/p\u003e \u003cp\u003e14.8 Conclusion 237\u003c\/p\u003e \u003cp\u003eReferences 237\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Biological Effect Nanotubular, Vanderwall’s Impact, of 4-Methyl-2-Nitroaniline (4M2NA) Nanocrystals 243\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSenthil Kannan K., Pauline Jenifer S., Divya R., Raju K., Gayathri A., Jemma Hermelin Jesy Diaz, Maria Sumathi B. and Flora G.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 244\u003c\/p\u003e \u003cp\u003e15.2 XRD and Computational Data 245\u003c\/p\u003e \u003cp\u003e15.3 Biological Activity: Antidiabetic (AD), Anti-Inflammatory (AI), and Antifungal (AF) Effect 251\u003c\/p\u003e \u003cp\u003e15.4 Conclusion, Outlook, and Future Aspects 251\u003c\/p\u003e \u003cp\u003eReferences 251\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Biomedical, Tribological, and Electronic Functionalities of Silver Nanoparticles 257\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eFlora G., Ganesan H., Maalmarugan J., Egbert Selwin Rose A., Dayana Lobo F., Divya R., Senthil Kannan K. and Sheeba M.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 258\u003c\/p\u003e \u003cp\u003e16.2 Tribological Data 258\u003c\/p\u003e \u003cp\u003e16.3 Influx 259\u003c\/p\u003e \u003cp\u003e16.4 HeLa Cell Line, Bacterial and Fungal Utility 259\u003c\/p\u003e \u003cp\u003e16.5 Conclusion 260\u003c\/p\u003e \u003cp\u003eReferences 261\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Commercialization of Nanovaccines: Utopia or a Reality? 267\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAmjad Islam Aqib, Tean Zaheer, Muhammad Usman, Muhammad Arslan and Khazeena Atta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 268\u003c\/p\u003e \u003cp\u003e17.2 Development of Nanovaccines 270\u003c\/p\u003e \u003cp\u003e17.3 Novel Adjuvants and Delivery System for Nanovaccines 270\u003c\/p\u003e \u003cp\u003e17.4 Success Story 272\u003c\/p\u003e \u003cp\u003e17.5 Nanovaccines in Human Health 273\u003c\/p\u003e \u003cp\u003e17.6 Nanovaccines in Animal Health 274\u003c\/p\u003e \u003cp\u003e17.7 Constraints in the Development and Application 276\u003c\/p\u003e \u003cp\u003e17.8 Issues Related to Product Application 277\u003c\/p\u003e \u003cp\u003e17.9 Characteristics of Nanoparticles Applicable to Public Health 278\u003c\/p\u003e \u003cp\u003e17.10 Conclusion 279\u003c\/p\u003e \u003cp\u003eReferences 280\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Functionalization of Nanobiomaterials in Nanovaccinology 283\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJyothy G. Vijayan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAbbreviations 283\u003c\/p\u003e \u003cp\u003e18.1 Introduction 284\u003c\/p\u003e \u003cp\u003e18.2 Characteristics of Functionalized Bionanoparticles 285\u003c\/p\u003e \u003cp\u003e18.3 Functionalization of NPs 285\u003c\/p\u003e \u003cp\u003e18.3.1 Functionalization With Different Ligands 285\u003c\/p\u003e \u003cp\u003e18.3.2 Polymer Functionalized NPs 286\u003c\/p\u003e \u003cp\u003e18.4 Nanomaterials for Vaccine Synthesis 286\u003c\/p\u003e \u003cp\u003e18.4.1 Gold NPS 286\u003c\/p\u003e \u003cp\u003e18.4.2 Silica NPs 286\u003c\/p\u003e \u003cp\u003e18.4.3 Calcium NPs 286\u003c\/p\u003e \u003cp\u003e18.4.4 Polymeric NPs 286\u003c\/p\u003e \u003cp\u003e18.4.5 Inorganic Magnetic NPs 287\u003c\/p\u003e \u003cp\u003e18.4.6 Chitosan NPs 287\u003c\/p\u003e \u003cp\u003e18.4.7 Liposomal NPs 287\u003c\/p\u003e \u003cp\u003e18.5 Role of the Surface of NPs on Vaccine Development 288\u003c\/p\u003e \u003cp\u003e18.6 Nanovaccines: Routes of Administration 288\u003c\/p\u003e \u003cp\u003e18.6.1 Intradermal Routes 288\u003c\/p\u003e \u003cp\u003e18.6.2 Intramuscular Routes 289\u003c\/p\u003e \u003cp\u003e18.6.3 Subcutaneous Routes 289\u003c\/p\u003e \u003cp\u003e18.6.4 Oral Routes 289\u003c\/p\u003e \u003cp\u003e18.6.5 Nasal Routes 289\u003c\/p\u003e \u003cp\u003e18.6.6 Tropical Routes 289\u003c\/p\u003e \u003cp\u003e18.6.7 Ocular Routes 289\u003c\/p\u003e \u003cp\u003e18.7 Nanovaccines for Different Applications 290\u003c\/p\u003e \u003cp\u003e18.7.1 Nanovaccines Against Bacteria 290\u003c\/p\u003e \u003cp\u003e18.7.2 Nanovaccines Against Pathogens 290\u003c\/p\u003e \u003cp\u003e18.7.3 Nanovaccines Against Viruses 290\u003c\/p\u003e \u003cp\u003e18.7.4 Nanovaccines Against Parasites 290\u003c\/p\u003e \u003cp\u003e18.7.5 Nanovaccines Against Cancer 291\u003c\/p\u003e \u003cp\u003e18.8 Emulsions 291\u003c\/p\u003e \u003cp\u003e18.9 Nanogels 291\u003c\/p\u003e \u003cp\u003e18.10 Virus-Like Particles (VLP) 292\u003c\/p\u003e \u003cp\u003e18.11 Applications of Novel Nanovaccines 293\u003c\/p\u003e \u003cp\u003e18.12 Applications of Functionalized Nanovaccines 293\u003c\/p\u003e \u003cp\u003e18.12.1 For Cancer Therapy 293\u003c\/p\u003e \u003cp\u003e18.12.2 Against Different Infectious Diseases 294\u003c\/p\u003e \u003cp\u003e18.13 Pros and Cons of Using Vaccines 294\u003c\/p\u003e \u003cp\u003e18.13.1 Toxicity of NPs 294\u003c\/p\u003e \u003cp\u003e18.14 Future Aspects 295\u003c\/p\u003e \u003cp\u003e18.15 Conclusions 295\u003c\/p\u003e \u003cp\u003eReferences 296\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Oral Nanovaccines Delivery for Clinical Trials and Commercialization 301\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eDominic Augustine, Pushpalatha C., Sowmya S.V., Chhaya Kumar, Elizabeth AbbuVarghese and Gayathri V.S.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 302\u003c\/p\u003e \u003cp\u003e19.2 Barriers to Oral Vaccines 302\u003c\/p\u003e \u003cp\u003e19.3 Evolution of Oral Nanovaccines 304\u003c\/p\u003e \u003cp\u003e19.4 Oral Delivery of Nanovaccines 305\u003c\/p\u003e \u003cp\u003e19.5 Immune Response to Oral Nanovaccines 306\u003c\/p\u003e \u003cp\u003e19.6 Oral Nanovaccines Carriers 307\u003c\/p\u003e \u003cp\u003e19.6.1 Natural Nanovaccine Carriers 307\u003c\/p\u003e \u003cp\u003e19.6.2 Synthetic Nanovaccine Carriers 308\u003c\/p\u003e \u003cp\u003e19.7 Formulation Strategies and Characterization of Oral Nanovaccines 310\u003c\/p\u003e \u003cp\u003e19.8 Regulations and Challenges for Oral Nanovaccines Delivery 312\u003c\/p\u003e \u003cp\u003e19.9 Future Perspectives 314\u003c\/p\u003e \u003cp\u003e19.10 Conclusion 314\u003c\/p\u003e \u003cp\u003eReferences 315\u003c\/p\u003e \u003cp\u003eIndex 319\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Clinical \u0026amp; internal medicine [\u003ca title=\"See our other books on Clinical \u0026amp; internal medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Clinical%20\u0026amp;%20internal%20medicine%20%5BMJ%5D%22\"\u003eMJ\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Scrivener","offers":[{"title":"Brand New","offer_id":52430980317464,"sku":"9781119857341","price":127.89,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781119857341.jpg?v=1784767535","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/nanovaccinology-as-targeted-therapeutics-hardback-9781119857341","provider":"Freshly Printed Books","version":"1.0","type":"link"}